Overview of the main clinical studies on tuberculosis drugs in Brazil and around the world
Vigil Sanit Debate, Rio de Janeiro, 2024, v.12: e02322 | Published on: 11/10/2024
DOI:
https://doi.org/10.22239/2317-269X.02322Keywords:
Tuberculosis, Drug, Clinical Trials, LandscapeAbstract
Introduction: This article provides a comprehensive overview of tuberculosis (TB) drug clinical trials conducted in Brazil and globally. TB is highlighted as one of the leading lethal infectious diseases, facing the growing challenge of drug resistance. Objective: The study aims to map recent advances and identify gaps and challenges in the search for effective treatments for TB, emphasizing Brazil’s contribution, which is known for its research in tropical diseases. Method: An analysis of clinical trials related to TB was conducted, focusing on the geographical diversity of the studies and the intersectoral collaboration between governments, academic institutions, and non-governmental organizations. The survey covered research at both national and international levels. Results: The results indicate a significant increase in the number of clinical trials, reflecting a growing interest and investment in research and development (R&D) aimed at combating TB. Regions with high disease incidence have received special attention. Collaboration between different sectors has been crucial in promoting progress. Conclusions: Despite the advances, the study underscores important challenges, such as the need for more R&D investments and the urgency of public policies to facilitate access to new drugs. The article highlights the importance of continuous and collaborative efforts in developing safe and accessible treatments, as well as the effective integration of innovations into the healthcare system, with special attention to vulnerable populations.
Downloads
Author Biographies
-
Sílvia Pereira da Silva Santos , Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz (Farmanguinhos/Fiocruz), Rio de Janeiro, RJ, Brasil
-
Flavia Maria Lins Mendes, Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, MS, Brasil
-
Wanise Borges Gouvea Barroso Borges Gouvea Barroso, Instituto de Ciência e Tecnologia em Biomodelos/Fiocruz | Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz (Farmanguinhos/ Fiocruz), Rio de Janeiro, RJ, Brasil
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Health Surveillance under Debate: Society, Science & Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
COPYRIGHT ALLOWANCE The author (s) hereinafter designated as the ASSIGNOR hereby assign and transfer, free of charge, the ownership of the copyrights related to this ARTICLE to the Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debate, represented by FUNDAÇÃO OSWALDO CRUZ, established at Av. Brasil, nº 4365, Manguinhos, Rio de Janeiro, RJ, Brazil, CEP 21045-900, under the conditions set out below: (a) The terms and conditions set forth in this Agreement shall apply to the following: 1. The ASSIGNOR declares that they s(he) is (are) the author (s) and owner (s) of the copyrighted property of the ARTICLE submitted. 2. The ASSIGNOR declares that the ARTICLE does not infringe the copyrights and / or other property rights of third parties, that the disclosure of images (if any) has been authorized and that they s(he) assume(s) full moral and / or property liability for its content, before third parties. 3. THE ASSIGNOR assigns and transfers all copyrights relating to the ARTICLE to the ASSIGNEE, especially the rights of editing, publication, translation into another language and reproduction by any process or technique. The ASSIGNEE becomes the exclusive owner of the rights related to the ARTICLE, and any reproduction, totally or partially, is prohibited in any other means of publicity, printed or electronic, without prior written authorization from the ASSIGNEE. 4. The assignment is free and, therefore, there will be no remuneration for the use of the ARTICLE by the ASSIGNEE.
